Adrenokortikalkarzinom (ACC)
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DIS-ADRENOCORTICAL-CARCINOMA |
|---|---|
| Art | Erkrankung |
| Aliase | ACCAdrenalkortikalkarzinomNebennierenrindenkarzinomKarzinom der NebennierenrindeАдренокортикальна карцинома (АКК) |
| Status | reviewed 2026-05-19 | pending_clinical_signoff |
| Erkrankungen | None declared |
| Quellen | SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 SRC-NCCN-NET-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8370/3 |
|---|---|
| icd_o_3_topography | ["C74.0"] |
| icd_10 | C74.0 |
| who_classification | WHO Endokrin und Neuroendokrin Tumore 5 ed (2022): Adrenal Kortikalkarzinom |
Anmerkungen
Adrenocortical carcinoma is an aggressive rare cancer of the adrenal cortex. Bimodal age distribution (pediatric and adult peaks) reflects two distinct biological contexts: pediatric ACC is overwhelmingly hereditary (Li-Fraumeni / Beckwith-Wiedemann), adult ACC is mostly sporadic with ~10% hereditary component. Functional ACC presents with hormonal syndromes: hypercortisolism (Cushing — most common, ~50% of functional ACC), virilization (androgen-secreting; especially in women), feminization (estrogen- secreting; rare; in men), Conn syndrome (aldosterone-secreting; rare). Non-functional ACC presents with mass effect, abdominal pain, or as incidental imaging finding. Staging: ENSAT (European Network for the Study of Adrenal Tumors) staging system; tumor size >6 cm, capsular invasion, regional nodes, distant metastasis are key prognostic factors. Mitotic count (Weiss score / Helsinki score) drives recurrence-risk stratification. Treatment fundamentals (full Indications pending): radical adrenalectomy with curative intent for resectable disease — open approach historically preferred (laparoscopic associated with positive-margin / peritoneal-seeding risk in retrospective series). Mito...
Verwendet von
Algorithmen
ALGO-ACC-1L- ALGO-ACC-1LALGO-CASCADE-LFS-CARRIER-FAMILY-TESTING- ALGO-CASCADE-LFS-CARRIER-FAMILY-TESTINGALGO-MEN1-CARRIER-SURVEILLANCE- ALGO-MEN1-CARRIER-SURVEILLANCEALGO-PEDIATRIC-CANCER-PREDISPOSITION-TRIAGE- ALGO-PEDIATRIC-CANCER-PREDISPOSITION-TRIAGE
Erkrankung
DIS-CYSTIC-NEPHROMA- Zystisches NephromDIS-WILMS- Wilms-Tumor (Nephroblastom)
Anwendungsgebiet
IND-ACC-1L-MITOTANE-EDP- IND-ACC-1L-MITOTANE-EDPIND-ACC-1L-RESECTION-MITOTANE- IND-ACC-1L-RESECTION-MITOTANE
Warnhinweis
RF-ACC-HIGH-RECURRENCE-RISK-BIOLOGY- Nachresektions-Adrenokortikalkarzinom mit hohem Rezidivrisiko — ENSAT-Stadium...RF-LI-FRAUMENI-CONFIRMED-CARRIER- Patient hat eine bestätigte keimlinien-TP53-pathogene Variante (positive keimlinien-Test, distinc...
Therapieschema
REG-EDP-M-ACC- EDP-M (etoposide + Doxorubicin + cisplatin + mitotane) — FIRM-ACT DosierungREG-MITOTANE-ADJUVANT-ACC- Mitotane adjuvante Monotherapie (ACC)
Quellen
SRC-ADIUVO-TERZOLO-2023- Adjuvant mitotane Versus Überwachung bei niedriggradigen, lokalisierten adrenokortikalen Karzinomen (A...SRC-ENSAT-ACC-2018- Europäische Gesellschaft für Endokrinologie Klinische Praxis Leitlinien für die Verwaltung von adren...SRC-ESMO-ACC-2020- Adrenalinkarzinome und maligne Phaeochromozytome: ESMO-EURACAN Klinische Praxis...SRC-FIRM-ACT-FASSNACHT-2012- Kombinationschemotherapie bei fortgeschrittenem adrenokortikalen Karzinom